Nav: Home

New drug combination restores beta cell function in animal model

February 20, 2020

The loss of the identity of insulin-secreting beta cells in the islet of Langerhans, a process also called beta cell dedifferentiation, has been proposed to be a main reason for the development of diabetes. If and how dedifferentiated beta cells can be targeted by pharmacological intervention for beta cell regeneration is unknown. In a new study in mice, Helmholtz Zentrum München in collaboration with Novo Nordisk, demonstrated for the first time that a targeted combinatorial drug treatment is able to restore beta cell function, achieve beta cell redifferentiation and therefore potentially open new ways for diabetes remission.

Under certain conditions, beta cells can lose their identity and regress to a less differentiated state in which they lose most of their prior functions. It has been proposed that this dedifferentiation contributes to an ongoing degenerative process of beta cell dysfunction. Current pharmacological diabetes treatments are not able to stop the decline of functional beta cell mass loss. The earlier this decline can be prevented, ideally already when first diabetic symptoms appear, the higher the amount and the level of beta cell function that will be preserved.

New target: Dedifferentiated beta cells

To investigate whether dedifferentiated beta cells can be targeted pharmacologically to restore beta cell function, the researchers used streptozotocin-induced diabetes in mice. Streptozotocin kills insulin-producing beta cells and causes severe diabetes. When injected in multiple low doses, however, some beta cells survive which replicates the decline in function the researchers wanted to establish for their experiment. Using single cell RNA sequencing the researchers could show that after streptozotocin treatment, the surviving beta cells dedifferentiate into a dysfunctional state. The simplicity of the model used (no genetic lesions nor autoimmunity) would help them better monitor the effect of the pharmacological treatment.

A good match: GLP-1/estrogen and insulin have additive effects in preclinical models

The team then tested treatments for their potential to restore beta cell function. To this end, they stratified seven cohorts of severely diabetic mice and treated them daily for 100 days with single and combinatorial pharmacology. The researchers showed that a stable Glucagon-like peptide-1 (GLP-1)/estrogen conjugate (provided by Novo Nordisk) enables targeted and selective delivery of the nuclear hormone cargo to beta cells. The combination of GLP-1/estrogen and a long acting insulin was superior to mono-treatments to both normalize glycemia, glucose tolerance, to increase pancreatic insulin content and to increase the number of beta cells. Importantly, administration of high doses of GLP-1/estrogen did not show signs of systemic toxicity in rats, a pre-requisite for any future clinical testing. In a collaboration with the biotech company InSphero, the researchers could also show that GLP-1/estrogen, but not GLP-1 or estrogen alone, increases human beta cell function when human pancreatic islets are exposed to cytokine stress, which is known to impair human beta cell function.

"Not only does our study describe paths and processes of beta cell dedifferentiation, it also demonstrates the potential of single and combinatorial drug treatments to achieve diabetes remission by targeting dedifferentiated beta cells" explains Prof. Dr. Heiko Lickert, director of the Institute for Diabetes and Regeneration Research at Helmholtz Zentrum München and Professor of Beta Cell Biology at TUM School of Medicine. "This is the first study that shows beta cell redifferentiation with targeted pharmacology performed by an interdisciplinary team that used cutting edge single cell technology, computational biology, pharmacology and regeneration biology" says Lickert who, together with Susanna M. Hofmann, Fabian Theis and Timo D. Müller at Helmholtz Zentrum München, lead this research project.

Future clinical studies?

This study brought together scientists from Helmholtz Zentrum München (Helmholtz Diabetes Center and Institute for Computational Biology), the German Center for Diabetes Research (DZD), Technical University of Munich (TUM) as well as InSphero AG and Novo Nordisk with the aim to explore the potential therapeutic benefits of GLP1/estrogen treatment in an animal models and in human cells in vitro. The results from this study as well as future studies to support translation to humans and safety of the compound may pave the way for clinical studies that use GLP-1 as a carrier peptide for estrogen but potentially also other, novel cargos to directly target beta cells for regenerative therapy and diabetes remission.

Helmholtz Zentrum München - German Research Center for Environmental Health

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.